文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用一种合成肽靶向雄激素受体（AR）可增加三阴性乳腺癌和表达AR的前列腺癌细胞系中的细胞凋亡。

Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.

作者信息

Jamshidi Mazdak, Keshavarzi Fatemeh, Amini Sabrieh, Laher Ismail, Gheysarzadeh Ali, Davari Kambiz

机构信息

Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran.

Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Cancer Rep (Hoboken). 2024 Jan;7(1):e1922. doi: 10.1002/cnr2.1922. Epub 2023 Oct 30.

DOI:10.1002/cnr2.1922
PMID:37903548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10809188/
Abstract

BACKGROUND: The androgen receptor (AR) has been studied as an approach to cancer therapy. AIMS: We used human breast cancer-derived cells with high, low, and very low expression levels of AR, in addition to prostate cancer-derived LNCaP and DU-145 cells as a positive and negative controls to examine apoptosis caused by a synthetic peptide that targets ARs. METHODS AND RESULTS: The peptide was produced to inhibit AR transactivation in breast cancer cell lines. We then measured cell viability, caspase-3 activity, and the ratio of Bax/Bcl-2. The findings indicated that the peptide (100-500 nM) in the presence of dihydrotestosterone (DHT) reduced cell growth in cells with high and low expression level of AR (p < .001), but not in cells with very low levels of AR. Treatment with 100-500 nM of peptide activated caspase-3 and increased the ratio of Bax/Bcl-2 in cells with high and low expression levels of AR. Also, increasing concentrations of the peptide (100-500 nM) reduced BrdU incorporation in the presence of DHT and promoted apoptosis in cells with high and low expression levels of AR (p < .001). CONCLUSION: The findings indicate the peptide significantly increased apoptosis in cancer cells.

摘要

背景：雄激素受体（AR）已作为一种癌症治疗方法进行研究。 目的：我们使用了人乳腺癌来源的细胞，其AR表达水平分别为高、低和极低，此外还使用了前列腺癌来源的LNCaP和DU - 145细胞作为阳性和阴性对照，以检测一种靶向AR的合成肽所引起的细胞凋亡。 方法与结果：该肽被制备用于抑制乳腺癌细胞系中的AR反式激活。然后我们测量了细胞活力、半胱天冬酶 - 3活性以及Bax/Bcl - 2的比率。结果表明，在存在二氢睾酮（DHT）的情况下，该肽（100 - 500 nM）可降低AR高表达和低表达细胞中的细胞生长（p < 0.001），但对AR极低表达的细胞无此作用。用100 - 500 nM的肽处理可激活AR高表达和低表达细胞中的半胱天冬酶 - 3并增加Bax/Bcl - 2的比率。此外，在存在DHT的情况下，增加肽的浓度（100 - 500 nM）可减少BrdU掺入，并促进AR高表达和低表达细胞中的细胞凋亡（p < 0.001）。 结论：研究结果表明该肽可显著增加癌细胞中的细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/906032b9709b/CNR2-7-e1922-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/1e81ed62ca01/CNR2-7-e1922-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/f6a8e1e8ea58/CNR2-7-e1922-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/9d41b055b866/CNR2-7-e1922-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/1d38ae30cfa9/CNR2-7-e1922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/c461fcafc0c0/CNR2-7-e1922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/3f5af2f7f02e/CNR2-7-e1922-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/906032b9709b/CNR2-7-e1922-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/1e81ed62ca01/CNR2-7-e1922-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/f6a8e1e8ea58/CNR2-7-e1922-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/9d41b055b866/CNR2-7-e1922-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/1d38ae30cfa9/CNR2-7-e1922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/c461fcafc0c0/CNR2-7-e1922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/3f5af2f7f02e/CNR2-7-e1922-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ed/10809188/906032b9709b/CNR2-7-e1922-g006.jpg

相似文献

[1]
Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.

Cancer Rep (Hoboken). 2024-1

[2]
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Cancer Res. 2004-10-1

[3]
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.

J Natl Cancer Inst. 2001-9-5

[4]
Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.

J Steroid Biochem Mol Biol. 2019-6-8

[5]
TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.

Prostate. 2008-2-15

[6]
Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.

Cancer Res. 2003-11-1

[7]
Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.

Cell Physiol Biochem. 2016

[8]
The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.

Oncotarget. 2016-12-20

[9]
6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.

Chem Biol Interact. 2016-10-5

[10]
Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.

Mol Cell Endocrinol. 1997-1-3

引用本文的文献

[1]
Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells.

Oncotarget. 2025-5-20

本文引用的文献

[1]
Anti-cancer peptide-based therapeutic strategies in solid tumors.

Cell Mol Biol Lett. 2022-4-9

[2]
Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study.

Healthcare (Basel). 2021-3-3

[3]
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.

Mol Cancer Ther. 2021-6

[4]
Androgen Receptor Regulates CD44 Expression in Bladder Cancer.

Cancer Res. 2021-6-1

[5]
Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.

Eur Rev Med Pharmacol Sci. 2021-2

[6]
BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca-dependent mPTP opening.

Cell Calcium. 2021-3

[7]
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.

J Transl Med. 2020-10-21

[8]
Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.

BMC Cancer. 2020-8-10

[9]
Role of Immunotherapy in Triple-Negative Breast Cancer.

J Natl Compr Canc Netw. 2020-4

[10]
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.

Biosci Trends. 2020-2-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索